University of Washington Medical Center	Original Effective Date:	Number:
1959 NE Pacific Street. Seattle, WA 98195	08-14-2018	PC-0068.03
Transfusion Services Laboratory	Revision Effective Date:	
Policies and Procedures Manual	03-27-2021	
<u> </u>		

**TITLE: Selection of Platelet Components** 

#### **PURPOSE:**

To provide guidance for selecting the appropriate platelet component for transfusion

# PRINCIPLE & CLINICAL SIGNIFICANCE:

Multiple platelet component types are stocked by the University of Washington Medical Center

Blood Bank (UWMC BB).

Blood Bank (UVVIVIC BB).				
Platelet Common Type Terminology		Description Benefits/Cons		
PAS - Platelet Additive Solution Platelets PAS Platelet		Collected by apheresis with the plasma replaced by Platelet Additive Solution, an electrolyte solution that replaces most of the plasma	Some hospitals are reporting a significant decrease in allergic transfusion reactions with the use of PAS as compared to plasma as a storage medium. The isoagglutinin titers are lower in PAS platelets when compared to apheresis in plasma platelets (less plasma, less antibodies)	
Apheresis Platelet in Plasma	Apheresis Platelet	Platelets collected by removing whole blood from the donor, separating the platelets for collection and returned the remaining components to the donor. Performed using a closed system. Takes approximately 2 hours to donate.	Provides an adult dose of platelets while exposing the recipient to only one donor  Donation takes more time than a whole blood donation	
Pre-Pooled	Pooled Platelet	Obtained from a standard whole blood donation after collection. The whole blood donation is centrifuged, and plasma and platelets pulled off into separate containers. 5 – 6 containers are pooled together into one.	Allows for bacterial testing using a culture method similar to apheresis platelets.  Less time to donate  An adult dose exposes the recipient to 4 to 6 donors	

Platelet Type	Common Terminology	Description	Benefits/Cons
HLA- selected*  HLA-Selected HLA- Matched HLA Platelets		Apheresis platelets stored in either plasma or PAS selected to avoid antigens to HLA antibodies of the intended recipient and/or antigen matched to the	Provide a therapeutic response in recipients who are platelet refractory due to HLA antibodies  Cost more than other
		recipient's HLA antigens	component types
Pathogen Reduced Platelet	Psoralen-treated PRT PR	Platelets collected by apheresis procedure using the INTERCEPT Blood System. The platelets are treated using psoralen/UVA light to inactivate infectious agents. This component may be collected in plasma or PAS and is labeled as "psoralen treated"	PRT platelet does NOT require irradiation.  Reduces the risk of transfusion-transmitted infectious agents including viruses, bacteria, parasite and protozoa. Eliminates the need for irradiation to prevent transfusion-associated graft-vs-host disease

<sup>\*</sup> refer to SOP HLA-Selected Platelets: Selecting Ordering Assigning and Releasing

#### **POLICIES:**

- All platelets issued for transfusion by the UWMC BB must meet the following requirements:
  - Leukocyte-reduced (residual leukocyte count <5x10<sup>6</sup>) and considered CMV safe
  - Irradiated or PRT (Pathogen reduced platelets) in order to reduce the risk of graftvs-host disease unless approved by the UWMC BB Medical Director (MD) (refer to SOP Irradiation of Blood Components)

NOTE: PRT (Pathogen reduced platelets) do not require irradiation

- Pre-Transfusion Test Requirements for issuing ABO specific plasma components:
  - 1 historical or current ABO/Rh performed at UWMC blood bank
- Issue of more than 2 platelet components in a 24-hour period to the same patient requires UWMC BB MD approval
- Pre and Post Bone Marrow Transplant (BMT) patients have special transfusion requirements to limit the volume of incompatible plasma transfused by volume reducing the platelet prior to issue. It is standard to volume reduce to 100 mL unless otherwise specified on order or by patient SQ history.
- Rh negative platelets should be provided for Rh negative patients. Rh positive substitutions are acceptable but required UWMC BB MD or provider approval.
  - Add the comment 'RHPAPP' (Rh Pos approved by Provider) to the Transfusion Record indicating MD approved

TITLE: Coloction of District Components	Number:
TITLE: Selection of Platelet Components	PC-0068.03

- PAS platelets, Apheresis platelets in plasma, and pre-pooled platelets may be used interchangeable UNLESS otherwise specified by:
  - o Recipient's transfusion plan (see "Comment" section in BAD file)
  - Provider order (see "Special Requirements section on Product Requisition and order in BOP)
  - Neonatal and intrauterine transfusions should not be issued pre-pooled platelets

### **INSTRUCTIONS:**

Patient Record Review - Verification of Special Requirements

**Selecting Rh Type** 

Selecting ABO Group for the Neonatal and Intrauterine Transfusion

**Selecting ABO Group for BMT Patient** 

Selecting ABO Group for the Adult Patient (NON-BMT patient)

Patient Record Review - Verification of Special Requirements

STEP	ACTION		
	Review the patient's history in Sunquest (SQ) ensuring complete review of the comment section for special platelet requirements such as:  Component type restrictions (i.e. HLA- matched, Apheresis only, PAS only)  Attributes: Irradiated, washed  Volume reduction		
	Comment	Definition	
	PAS or RV out of group PLT or RV out of group PLT	<ul> <li>Any ABO PAS platelet may be issued at full volume</li> <li>ABO incompatible platelets, stored in plasma, should be volume reduced to 100 mL</li> </ul>	
	PAS or RV PLT A/O or RV PLT A/O	<ul> <li>Any ABO PAS platelet may be issued at full volume</li> <li>Group A or O platelets, stored in plasma, should be volume reduced to 100 mL</li> </ul>	
1	PAS or RV PLT B/O or	Any ABO PAS platelet may be issued at full volume	
	RV PLT B/O	<ul> <li>Group B or O platelets, stored in plasma, should be volume reduced to 100 mL</li> </ul>	
Ý	PAS or RV PLT A/B/O	Any ABO PAS platelet may be issued at full volume	
	RV PLT A/B/O	<ul> <li>Group A, B or O platelets, stored in plasma, should be volume reduced to 100 mL</li> </ul>	
	PAS or RV All PLT due to TRRX	<ul> <li>Any ABO PAS platelet may be issued at full volume</li> <li>All ABO group platelets, stored in plasma, should be volume reduced to 100 mL</li> </ul>	
	RV ALL PLT due to VOLO	Volume reduce all platelets regardless of ABO group or component type (PAS or Plasma)	

TITI C. Coloction of Blotolet Components	Number:
TITLE: Selection of Platelet Components	PC-0068.03

STEP	ACTION		
2	Review the product order for the following:  Attributes  Special requirements		
	Discrepancies between patient history and order requirements	Then	
	NO	Go to next step	
3	YES	<ul> <li>Add new attributes or special requirements to the patient record in SQ</li> <li>Resolve before selecting blood components</li> <li>Consult with a UWMC BB MD or manager for resolution, if needed</li> </ul>	
	If patient	Then	
4	Requires HLA-selected platelet	<ul> <li>Refer to SOP HLA Selected Platelets to select and assign a platelet</li> <li>Go to next section</li> </ul>	
	Does not require HLA-selected platelets	Go to next section	

**Selecting Rh Type** 

STEP	ACTION				
	Review the following to determine what Rh type to select     BAD file     Historical ABO/Rh performed at UWMC blood bank     Comments      Rh Compatibility Table				
	Recipient Clinical	Recipient	1	et Rh	
	Profile	Rh	Positive	Negative	
		Positive	✓	✓	
1	Adult Recipient	Negative	Only with BB MD or provider approval	✓	
		No Rh in BAD	Review SQ COMM for acceptable Rh	MENTs carefully	
	Neonate	Positive	✓	✓	
	Neonate	Negative	NA	✓	
		Maternal	Platelet Rh		
	IUT	Rh	Positive	Negative	
		Positive	✓	✓	
		Negative	NA	✓	

Number: PC-0068.03

STEP	ACTION	
2	<ul> <li>Contact the UWMC Medical Director for approval to substitute Rh positive platelets when Rh negative platelets are not available</li> <li>Add a RHPAPP (Rh Pos approved by Provider) comment to the Transfusion Record indicating MD approved – this comment is not required when issuing blood components to the operating room, for a bleeding emergency situation, or</li> </ul>	
	as part of a Massive Transfusion Protocol	
3	Go to the appropriate section for guidance on selecting the acceptable ABO group  • Selecting ABO Group for the Neonatal and Intrauterine Transfusion  • Selecting ABO Group for BMT Patient  • Selecting ABO Group for the Adult Patient (not a BMT Patient)	

STEP	ACTION			
	If transfusion is for Then			
1	Neonatal		Go to step 2	
	Intrauterine Tr	ansfusion	Go to step 3	
		ect Platelets according to the following table for neonatal transfusion  • Pooled platelets are not acceptable for neonatal transfusion		
	Fooled	NEONATAL 7		
	Recipient ABO	PAS Platelets	Platelets in Plasma	
2	А	O, A, B, AB	A, AB	
	В	O, A, B, AB	B, AB	
	0	O, A, B, AB	O, A, B, AB	
	AB	O, A, B, AB	AB	
	<ul> <li>Select platelets for intrauterine I transfusion according to the following table</li> <li>Rh type negative platelets should be provided if the mother is Rh neg</li> <li>Contact the patient UWMC Medical Director for selection if a group AB platelet is not available</li> </ul>			
3		Intrauterine	<b>Fransfusion</b>	
	Neonate	Platelet ABO		
	All	AB	AB	
4	Perform additional component processing required –see SOP <i>Blood Component</i> Processing and process specific SOP			

TITLE: Colortion of Blotalet Commonweals	Number:
TITLE: Selection of Platelet Components	PC-0068.03

**Selecting ABO Group for BMT Patient** 

STEP	ACTION			
	Review the "COMMENTs" section of the par	tient's BAD file special platelet requirements  Then		
1	Pre-BMT	Go to next step		
	Post-BMT or Donor ABO/Rh is indicated in recipients BAD file	Go to step 3		

Select platelets for pre-BMT patients according to the following table:

	Pre-Bone Marrow Transplant				
	Daginiant		NON-PAS		
2	Recipient ABO	PAS ABO	Full Volume ABO	Reduced Volume ABO	
	Α	O, A, B, AB	A, AB	B, O	
	В	O, A, B, AB	B, AB	A, O	
	0	O, A, B, AB	O, A, B, AB	None	
	AB	O, A, B, AB	AB	A, B, O	

Select platelets for **post-BMT** patients according to the following table:

	Post-Bone Marrow Transplant						
	Recipient ABO	Denor SO BA	SQ BAD		NON-PAS		
		Donor ABO	ABO PAS	Full Volume	Reduced Volume		
		0	0	O, A, B, AB	O, A, B, AB	none	
3	0	Α	NTD	O, A, B, AB	A, AB	B, O	
		В	NTD	O, A, B, AB	B, AB	A, O	
		AB	NTD	O, A, B, AB	AB	A, B, O	
	A	0	NTD	O, A, B, AB	A, AB	B, O	
		Α	Α	O, A, B, AB	A, AB	B, O	
		В	NTD	O, A, B, AB	AB	A, B, O	
		AB	NTD	O, A, B, AB	AB	A, B, O	
	В	0	NTD	O, A, B, AB	B, AB	A, O	
		Α	NTD	O, A, B, AB	AB	A, B, O	
		В	В	O, A, B, AB	B, AB	A, O	
		AB	NTD	O, A, B, AB	AB	A, B, O	

TITLE: Coloction of Distalct Components	Number:
TITLE: Selection of Platelet Components	PC-0068.03

STEP	ACTION					
		0	NTD	O, A, B, AB	AB	A, B, O
	АВ	Α	NTD	O, A, B, AB	AB	A, B, O
		В	NTD	O, A, B, AB	AB	A, B, O
		AB	NTD	O, A, B, AB	AB	A, B, O
4	Perform any additional component processing required –see SOP <i>Blood Component Processing</i> and process specific SOP					

Selecting ABO Group for the Adult Patient (NOT a BMT patient)

Selecting ABO Group for the Adult Patient (NOT a BMT patient)					
STE	ACTION				
Р		7.01.014			
1	Select ABO group specific platelets if available and inventory management is not a consideration (platelet is needed for a different patient or to prevent discarding				
•	platelets due	platelets due to expiration)			
	Use this table	as guide for selection of AE	O group specific platelet		
	General ADULT Population (not BMT)				
	Recipient ABO	PAS Non-PAS			
2	А	O, A, B, AB	A, B, AB, reduced volume O		
	В	O, A, B, AB	B, A, AB, reduced volume O		
	0	O, A, B, AB	O, A, B, AB		
	AB	O, A, B, AB	AB, A, B, reduced volume O		
	Perform any component processing required –see SOP Blood Component Processing and process specific SOP				

# CALCULATIONS/INTERPRETATIONS/RESULTS REPORTING/NORMAL VALUES/CRITICAL VALUES

#### Interpretation

None

# **Results Reporting in Sunquest**

None

#### **CALIBRATION:**

None

#### PROCEDURE NOTES AND LIMITATIONS:

"BMT" listed in the patient's SQ "comment" field designates the patient is a bone marrow transplant candidate. The date of transplant and donor type will be listed for SCCA patients when UWMC BB is provided this information from the SCCA TSO office. The recipient should

TITLE: Selection of Platelet Components	Number:	
THEL. Selection of Flatelet Components	PC-0068.03	

be considered post-BMT on the day of transplant. Non-SCCA BMT recipient transplant date and donor ABO/Rh may be added if known.

#### **REFERENCES:**

#### **RELATED DOCUMENTS:**

SOP Irradiation of Blood Components SOP HLA-Selected Platelets SOP Blood Component Processing

# **APPENDIX:**

# TITLE: Selection of Platelet Components Number: PC-0068.03

UWMC SOP Approval:					
UWMC CLIA Medical Director	Mark H. Wener, MD	Date			
Transfusion Service Manager		Date			
Compliance Analyst	Nina Sen	Date			
Transfusion Service	Christine Clark	Bute			
<b>Medical Director</b>	Monica B. Pagano, MD	Date			
<b>UWMC Biennial Re</b>	eview:				
		Date			
		Date			

#### **REVISION:**

#### 12-02-18:

To clarify the policy for selection of platelets for the general adult population the following revisions were made:

- Removed the policy statement for restricting plasma by volume
- Updated the table for selecting platelet for the General Adult Population
  - Add reduced volume O to group A, B, AB recipients
- Removed "ABO Compatibility" from table titles.

Change the group AB BMT patient BAD file ABO to NTD

#### 02-25-21:

Added Pathogen Reduced Platelets as a new platelet type. Pathogen reduced platelets do not require irradiation. Updated RV SQ instructions due to transfusion reactions.